Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 4:40 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 3,285 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Progenitor Cells Clear all
Terminated Phase 2Phase 3 Interventional Results available

Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

NCT00630565
View directory record Official record
Conditions
Leukemia
Interventions
sargramostim, busulfan, cyclophosphamide, dexamethasone, etoposide, bone marrow transplantation, hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Nov 1, 2026, 4:40 AM EST
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

NCT04653246
View directory record Official record
Conditions
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
Interventions
Isatuximab, Lenalidomide, Bortezomib Injection, Dexamethasone
Drug
Lead sponsor
Jacob Laubach, MD
Other
Eligibility
75 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Nov 1, 2026, 4:40 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Pharmacokinetics of Granulocyte Colony Stimulating Factor in the Breast Milk of Volunteer Peripheral Blood Stem Cell Donor

NCT02322151
View directory record Official record
Conditions
Normal Physiology
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 60 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Nov 1, 2026, 4:40 AM EST
Completed Phase 1Phase 2 Interventional Results available

Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene

NCT01852071
View directory record Official record
Conditions
ADA-SCID
Interventions
Infusion of autologous EFS-ADA LV CD34+ (OTL-101), busulfan, PEG-ADA ERT
Genetic · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
1 Month to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Los Angeles, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Nov 1, 2026, 4:40 AM EST
Completed No phase listed Observational

Survey of the Need for Information on Fertility and Menopause-Related Treatment Effects Among HSCT Patients

NCT00429455
View directory record Official record
Conditions
Stem Cell Transplantation
Interventions
Survey
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Nov 1, 2026, 4:40 AM EST
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

NCT00006747
View directory record Official record
Conditions
Graft Versus Host Disease, Lymphoma
Interventions
carmustine, melphalan, etoposide, cytarabine, tacrolimus, methotrexate, sargramostim, transplant
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 59 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
48
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Nov 1, 2026, 4:40 AM EST
Withdrawn No phase listed Observational

Study in Adult and Pediatric Patients With HSCT-TMA

NCT04970004
View directory record Official record
Conditions
Stem Cell Transplant Complications, Thrombotic Microangiopathies
Interventions
No intervention
Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
1 Month and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Nov 1, 2026, 4:40 AM EST
Active, not recruiting Phase 1 Interventional

Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT

NCT05095532
View directory record Official record
Conditions
Chronic Pancreatitis, Mesenchymal Stem Cells
Interventions
Bone marrow-derived mesenchymal stem cells, Placebo
Biological · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 1, 2026, 4:40 AM EST
Completed Phase 1Phase 2 Interventional Results available

Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.

NCT00325416
View directory record Official record
Conditions
Multiple Myeloma
Interventions
melphalan, topotecan (TPT), Autologous Stem Cell Rescue
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Nov 1, 2026, 4:40 AM EST
Completed Not applicable Interventional

Proteomics and Stem Cell Therapy as a New Vascularization Strategy

NCT02802852
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Pneumatic calf compression, Filgrastim
Device · Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
35 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Nov 1, 2026, 4:40 AM EST
Completed Phase 2 Interventional

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation

NCT00003963
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, vinorelbine ditartrate
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Nov 1, 2026, 4:40 AM EST
Completed Phase 2 Interventional Results available

Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation

NCT01491958
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
Interventions
atorvastatin, Tacrolimus, methotrexate
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Nov 1, 2026, 4:40 AM EST
Completed Phase 2 Interventional

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation

NCT01562158
View directory record Official record
Conditions
Acquired Bleeding Disorder, Bleeding During/Following Surgery
Interventions
standard therapy, activated recombinant human factor VII, placebo
Procedure · Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Nov 1, 2026, 4:40 AM EST
Terminated Phase 1 Interventional

Study of the Effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin to Treat Chronic Wounds

NCT01751282
View directory record Official record
Conditions
Non Healing Wounds
Interventions
Stem Cell
Genetic
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Nov 1, 2026, 4:40 AM EST
Completed Not applicable Interventional Results available

Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant

NCT01852591
View directory record Official record
Conditions
Multiple Myeloma
Interventions
PCV 13
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Nov 1, 2026, 4:40 AM EST
Completed No phase listed Observational Accepts healthy volunteers

The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies

NCT00001432
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Healthy, Hematologic Neoplasm, Lymphoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 1, 2026, 4:40 AM EST
Withdrawn Phase 1Phase 2 Interventional

Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma

NCT02724904
View directory record Official record
Conditions
Lymphoma
Interventions
Allogeneic stem cell transplantation, Fludarabine, Thiotepa, Methotrexate
Procedure · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Nov 1, 2026, 4:40 AM EST
Recruiting No phase listed Observational

Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients

NCT05234723
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
Not listed
Lead sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Nov 1, 2026, 4:40 AM EST
Completed Phase 3 Interventional

Bone Marrow Aspirate Concentrate (BMAC) for Treatment of Critical Limb Ischemia (CLI)

NCT01245335
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
BMAC injection, Placebo injection
Device
Lead sponsor
Harvest Technologies
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Birmingham, Alabama • El Dorado, Arkansas • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Nov 1, 2026, 4:40 AM EST
Recruiting Not applicable Interventional

Safety, Tolerability, and Efficacy of Enteral Nutrition Versus Standard of Care Nutrition in Hematopoietic Stem Cell Transplant Patients: A Pilot Study

NCT06004063
View directory record Official record
Conditions
Stem Cell
Interventions
Enteral nutrition (EN), Standard care parenteral nutrition (PN)
Dietary Supplement · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 1, 2026, 4:40 AM EST
Terminated Not applicable Interventional

Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant

NCT02326675
View directory record Official record
Conditions
Mucositis, Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Stomatitis
Interventions
Ice, Normal Saline Solution
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Nov 1, 2026, 4:40 AM EST
Completed Phase 2 Interventional Results available

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

NCT02869633
View directory record Official record
Conditions
Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Follicular Lymphoma, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Ibrutinib, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
5
States / cities
Birmingham, Alabama • Palo Alto, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Nov 1, 2026, 4:40 AM EST
Active, not recruiting No phase listed Observational

Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

NCT01608152
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Focus Group, Internet-Based Intervention, Interview
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 39 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 1, 2026, 4:40 AM EST
Completed Phase 2 Interventional Results available

Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant

NCT00597714
View directory record Official record
Conditions
Hodgkin's Disease, Non Hodgkin's Lymphoma, Myeloma, Leukemia, Myelodysplasia
Interventions
Non-myeloablative Stem Cell Transplantation
Drug
Lead sponsor
David Rizzieri, MD
Other
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Nov 1, 2026, 4:40 AM EST